Abstract: Novel tools and techniques might provide for implementing application, service, and/or content access control. Based at least in part on a consumer's choice of applications, services, content, and/or content providers—particular in exchange for a subsidy on content and/or network access fees provided to the consumer by chosen content providers—, a computing system may determine whether access to applications, services, and/or content not associated with the chosen content providers (“other content”) should be allowed or restricted. If restricted, the computing system might utilize various network access techniques and/or technologies to block the consumer's access to the other content, to allow access to the other content on a charge per access basis, or to allow access to the other content at reduced network access speeds. In some embodiments, an access provider (e.g., an Internet service provider, etc.) might perform both determination and implementation of content access and restriction.

Abstract: A method and apparatus of limiting power of a boiling water nuclear reactor system includes a reactor pressure vessel, a reactor core disposed in the reactor pressure vessel, a core shroud surrounding the reactor core, a downcomer region disposed between an inner surface of the reactor pressure vessel and the core shroud, a steam line connected to an upper end of the reactor pressure vessel and a condenser system that receives steam from the reactor pressure vessel. A portion of the condenser system condensate is returned to the reactor pressure vessel of the boiling water reactor inside the core barrel above the core rather than into the downcomer. Returning the condensate in this way increases the effectiveness of an isolation condenser system or if the condensate is a portion of the feedwater from the main condenser it provides an effective means to regulate core flow and core power.

Abstract: Novel tools and techniques are provided for implementing network experience shifting, and, in particular embodiments, using either a roaming or portable hypervisor associated with a user or a local hypervisor unassociated with the user. In some embodiments, a network node in a first network might receive, via a first network access device in a second network, a request from a user device to establish roaming network access, and might authenticate a user associated with the user device, the user being unassociated with the first network access device. Based on a determination that the user is authorized to access data, content, profiles, and/or software applications that are accessible via a second network access device, the network node might establish a secure private connection through a hypervisor or container communicatively coupled to the first network access device to provide the user with access to her data, content, profiles, and/or software applications.

Abstract: The present disclosure provides certain processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile (Compound 1) and certain polymorphs thereof. Also provided are pharmaceutical compositions comprising a crystalline polymorph form of Compound 1 and processes for preparing such polymorph forms.

Abstract: Provided herein are novel compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds described herein are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.

Abstract: Provided herein are Compounds having the following structure: wherein A, L, X and ring B are as defined herein, compositions comprising an effective amount of a Compound and methods for treating or preventing cancer, hypoxia, diabetes, stroke, autoimmune disease or a condition treatable or preventable by inhibition of Chk2, the ATM-Chk2 pathway or RSK2 comprising administering an effective amount of a Compound to a patient in need thereof.

Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.

Abstract: The present invention provides methods of treating a lymphoma (e.g.

Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.

Abstract: The present invention provides methods of treating an autoimmune disorder (e.g., lupus erythematosus, multiple sclerosis, myasthenia gravis, vasculitis and diabetes mellitus) in a subject by administering to the subject a therapeutically effective amount of one or more compounds of the invention.

Abstract: Disclosed is a method of halogenating the ring of an aromatic compound. The aromatic compound is contacted with a halogenating agent in the presence of a heterogeneous catalyst. The catalyst is the calcination reaction product of: (A) 51 to 99 wt % of a support which comprises at least one inorganic oxide or hydroxide of at least one metal that is at least divalent and forms a metal-to-oxygen matrix during calcination; and (B) 1 to 49 wt % of at least one dopant which comprises a compound that places an element that is at least divalent, bonded to oxygen atoms, into said matrix during said calcination, resulting in the formation of an acidic solid.

Abstract: Disclosed is a method of making a mercaptan by reacting hydrogen sulfide with an olefin in the presence of a heterogeneous acidic catalyst. The catalyst can be made by calcining a mixture of a hydroxide, such as Zr(OH).sub.4 or Ti(OH).sub.4, with an acidic site donor, such as H.sub.2 SO.sub.4, (NH.sub.4).sub.2 SO.sub.4, or WO.sub.3.

Abstract: Disclosed is a method of halogenating the ring of an aromatic compound. The aromatic compound is contacted with a halogenating agent in the presence of a heterogeneous catalyst. The catalyst is the calcination reaction product of:(A) 51 to 99 wt % of a support which comprises at least one inorganic oxide or hydroxide of at least one metal that is at least divalent and forms a metal-to-oxygen matrix during calcination; and(B) 1 to 49 wt % of at least one dopant which comprises a compound that places an element that is at least divalent, bonded to oxygen atoms, into said matrix during said calcination, resulting in the formation of an acidic solid.

Abstract: Disclosed is a method of making a mercaptan by reacting an aliphatic alcohol with hydrogen sulfide in a continuous gaseous phase reaction. The reaction is performed in the presence of a catalyst which comprises a catalytically active carrier that contains base and/or acid active sites, an alkali metal or alkaline earth metal bicarbonate, carbonate, oxide, or hydroxide, and a transition metal acid or alkali metal or alkaline earth metal salt thereof. Selectivities of close to 100% are obtained.